| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae10212794160b34478f0d05b6ab6fd7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-724
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-724
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 |
| filingDate |
2001-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4b65d1611206c8b5dd8443583663c64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fb3dd4882892d04478e8eedbc606f50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4cb0d2bfaef77a63b3757995897fce3 |
| publicationDate |
2006-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1676577-A1 |
| titleOfInvention |
Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide |
| abstract |
This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment orprevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10702540-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1684758-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1684758-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022029430-A1 |
| priorityDate |
2000-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |